Although these targeted therapies have greatly improved the prognosis of patients with advanced BRAF-mutant melanoma, they also have two major limitations: on the one hand, acquired resistance to BRAF inhibition typically develops after a median of 9–12 mo (Larkin et al, 2014; Long et al, 2015; Dummer et al, 2018). This evidence concerns the gene BRAF and melanoma.